Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib vs docetaxel in previously treated advanced or recurrent NSCLC
jRCT1080220402Phase 3
- Sponsor
- AstraZeneca
- Start
- Jun 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Gefitinib with Docetaxel (2 arms). Primary endpoint: Overall survival.
02
Drugs
gefitinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT1080220402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080220402.